This study was designed to test the effects of intracerebroventricularly (i.c.v.) administered CDP-choline (cytidine-5 0 -diphosphate-choline; citicoline) and its metabolites in rat models of inflammatory and neuropathic pain. The i.c.v. administration of CDP-choline (0.5, 1.0 and 2.0 lmol) produced a dose and time-dependent reversal of mechanical hyperalgesia in both carrageenan-induced inflammatory and chronic constriction injury-induced neuropathic pain models in rats. The antihyperalgesic effect of CDP-choline was similar to that observed with an equimolar dose of choline (1 lmol). The CDP-cholineinduced antihyperalgesic effect was prevented by central administration of the neuronal high-affinity choline uptake inhibitor hemicholinium-3 (1 lg), the nonselective nicotinic receptor antagonist mecamylamine (50 lg), the a7-selective nicotinic ACh receptor antagonist, a-bungarotoxin (2 lg) and the c-aminobutyric acid B receptor antagonist CGP-35348 (20 lg). In contrast, i.c.v. pretreatment with the nonselective opioid receptor antagonist naloxone (10 lg) only prevented the CDP-choline-induced antihyperalgesic effect in the neuropathic pain model while the nonselective muscarinic receptor antagonist atropine (10 lg) did not alter the antihyperalgesic effect in the two models. These results indicate that CDP-choline-elicited antihyperalgesic effect in different models of pain occurs through mechanisms that seem to involve an interaction with supraspinal a7-selective nicotinic ACh receptors, and c-aminobutyric acid B receptors, whereas central opioid receptors have a role only in the neuropathic pain model.
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Introduction
Cytidine-5 0 -diphosphate-choline; citicoline (CDP-choline) is an endogenously synthesized mononucleotide, composed of choline and cytidine (Weiss, 1995) , that affects numerous cellular actions in different experimental models (Adibhatla and Hatcher, 2002) . Orally, intravenously or intracerebroventricularly (i.c.v.) administered CDP-choline is rapidly metabolized to choline and cytidine/uridine, which leads to increased plasma and tissue concentrations of these metabolites (Lopez GCoviella et al., 1987; Wurtman et al., 2000) . Choline is the main hydrolysis product of CDP-choline and is also a precursor for the synthesis of the cholinergic neurotransmitter acetylcholine (ACh). Treatments that raise plasma and tissue choline levels increase the rates of synthesis (Cohen and Wurtman, 1975) and release of ACh (Ulus et al., 1989) and increase the level of cholinergic neurotransmission (Arslan et al., 1991) . In addition, choline is a full agonist for the a7-nicotinic ACh receptor (Papke et al., 1996; Alkondon et al., 1997; 1999) and shows near equimolar potency at peripheral a9a10 nAChRs (Vincler et al., 2006) . It has long been known that the direct and indirect activation of the cholinergic system produces analgesia in both animals and humans (Yaksh et al., 1985; Bartolini et al., 1992; Gurun et al., 1997; Kaya et al., 2004) . Furthermore, the activation of neuronal nAChRs in several central nervous system (CNS) regions produces antinociception in a variety of acute or chronic pain models in animals (Flores, 2000; Decker et al., 2004) . Various subtypes of nAChRs expressed in the mammalian brain can be constructed from different subunit combinations (Alkondon and Albuquerque, 1993; Sargent, 1993) . The a4b2 and a7 subtypes are strong candidates for involvement in pain modulation because of their distribution in neuronal pathways (Wada et al., 1989; Seguela et al., 1993) . Neurotransmitter release plays a critical role in producing the antinociceptive effects of nAChR activation, which in turn might increase the release of a number of neurotransmitters in the brain, including g-aminobutyric acid (GABA) and endogenous opioid peptides (Houdi et al., 1991; Dani and Bertrand, 2007) . In light of these observations, we recently demonstrated that centrally injected CDP-choline induced dosedependent and time-dependent antinociceptive effects without any motor impairment, in models of acute pain in rats (Hamurtekin and Gurun, 2006; Hamurtekin et al., 2007) . In this study, we aimed to investigate the possible antihyperalgesic effect of CDP-choline on a carrageenaninduced model of inflammatory pain and a chronic constriction injury (CCI) model of neuropathic pain in rats. These models of inflammatory and neuropathic pain were chosen because carrageenan is an inflammatory agent often used as a tool to investigate inflammatory hyperalgesia (Winter and Flatakeri, 1965) and CCI is one of the most frequent models used as a tool to investigate neuropathic pain in rats (Bennett and Xie, 1988) .
Methods

Subjects
Adult male Sprague-Dawley rats (200-350 g; Experimental Animals Breeding and Research Center, Uludag University Medical Faculty, Bursa, Turkey) were used. The subjects were housed in groups of five on soft bedding with food and water freely available, in a temperature-controlled (23 ± 11C) environment with a 12 : 12 h light-dark cycle. The subjects were allowed to habituate to the housing facilities for at least one week before surgery or behavioral testing. All experiments were performed according to the Ethical Guidelines of the International Association for the Study of Pain (Zimmermann, 1983 ) and all procedures were approved by the Uludag University Local Ethical Committee on Laboratory Animal Care and Use.
Experimental inflammatory pain model
Carrageenan, when injected subcutaneously into the plantar surface of a paw, produces a characteristic inflammation and associated hyperalgesia. After baseline testing, subjects were briefly anesthetized with ether and received a unilateral injection of l-carrageenan (100 ml, 2%) into the plantar surface of the right hindpaw. The contralateral hindpaw was untreated.
Experimental neuropathic pain model
CCI was performed in rats as described previously (Bennett and Xie, 1988) , but with slight modifications. Body weight of rats was 200-250 g at the time of surgery. Anesthesia was induced and maintained by ether and the left sciatic nerve was exposed at mid-thigh level and two 4-0 chromic gut sutures were loosely ligated around the sciatic nerve approximately 1 mm apart. The incision was closed with 4-0 silk suture. Any subjects that subsequently showed behavioral disturbances unrelated to the nerve injury procedure were excluded from further behavioral testing.
Behavioral measurements
The nociceptive thresholds of the hindpaw were determined for left and right hindpaws by using the Randall-Selitto paw pressure technique (Randall and Selitto, 1957) . The analgesia meter (Ugo Basile, Varese, Italy) applied a constant rate of increasing pressure (16 g/s) to the hindpaws. To prevent mechanically induced injury, a cutoff of 300 g (in inflammatory pain) and 250 g (in neuropathic pain) were used. The rats were trained in the nociceptive test daily for two days before any experiments or surgery were performed to stabilize baseline responses (Taiwo et al., 1989) . During the adaptation procedure, hind-paws were alternately tested three times with a 5-min inter-trial interval. All behavioral tests were conducted between 09 : 00 and 16 : 00 h. No differences in baseline paw withdrawal thresholds were noted as a function of time of day.
In the carrageenan-induced pain model, after carrageenan administration the rats were placed in a plexiglass box for observation. Consistent with previous reports (Gurun et al., 2009) , carrageenan induced acute, restricted inflammation associated with mechanical hyperalgesia, and withdrawal thresholds were strongly reduced for 3-6 h after carrageenan injection. This significant and long-lasting reduction of mechanical paw withdrawal thresholds from baseline scores was used to indicate an increased sensitivity level (hyperalgesia). Accordingly, 3 h after the carrageenan injection, paw withdrawal thresholds were determined for left and right hindpaws.
In the CCI-induced neuropathic pain model, after recovering from anesthesia the rats were placed in their cages and observed daily for signs of neuropathic pain, including limping, guarding of the affected limb, and weight loss. After a 13-day postsurgical recovery, the rats were tested for baseline sensitivity to mechanical stimulation of the plantar surface of both hindpaws. Significant and long-lasting reduction of the mechanical paw withdrawal threshold from baseline scores was used to indicate an increased sensitivity level (hyperalgesia). Paw withdrawal thresholds were determined for the ipsilateral left hindpaw of each rat.
Intracerebroventricular injection technique
For i.c.v. drug injections, the rats were implanted with a guide cannula under ether anesthesia, according to the method previously described by Hamurtekin et al. (2007) (Hamurtekin and Gurun, 2006) . Coordinates for the lateral cerebral ventricle were 1.5 mm lateral to the midline, 1.0 mm posterior to the bregma, and 4.5 mm ventral to the skull surface. According to these coordinates a 21-gauge stainless steel hypodermic tube guide cannula was lowered 4.2 mm below the surface of the skull and was fixed to the skull with acrylic cement. At the end of the surgical procedure, rats were housed in individual cages and allowed to recover from anesthesia for 4-5 h. During this period, rats did not show any sign of pain. i.c.v. injections were made through a 25-gauge stainless steel injection cannula inserted through and extending 0.3 mm beyond the guide cannula. The drug injections were performed on the day following i.c.v. cannulation. The injection cannula was attached to a 50-ml Hamilton microsyringe with PE-50 tubing, which was filled with saline or saline containing the desired dose of the drug of interest in 10 ml of solution. Drugs were then infused slowly within 30 s; after the injection the cannula was left in place for an additional 30 s to minimize flow of the drug solution back up the injector track. The volume for i.c.v. injection was 10 ml throughout the study. The volume injected was monitored by observing the movement of an air bubble placed in the polyethylene tubing. At the end of the experiments, the ventricular cannula placement was verified in some rats (40%) by injecting 10 ml of diluted (1 : 10) India ink. Brains were examined macroscopically after sectioning.
Experimental procedures
Subjects were randomly assigned to control or treated groups. Each rat was used once only and euthanized at the end of the experiment.
In the first set of experiments, rats received various doses of CDP-choline (0.5, 1, and 2 mmol; i.c.v.) or saline (10 ml; i.c.v.); subsequently mechanical paw withdrawal threshold was determined at 5, 10, 15, 20, 30, 40, 50 , and 60 min after injection.
In the second set of experiments, equimolar doses of choline (1 mmol) or cytidine (1 mmol) were injected i.c.v. Subsequently the mechanical paw withdrawal threshold was determined at 5, 10, 15, 20, 30, 40, 50 , and 60 min after injection.
In a third set of experiments atropine (10 mg; 0.0144 mmol), mecamylamine (50 mg; 0.2459 mmol), a-bungarotoxin (a-BgTx) (2 mg; 0.0003 mmol), hemicholinium-3 (HC-3) (1 mg; 0.0018 mmol), or saline (10 ml) was injected i.c.v. 15 min before CDP-choline (1 mmol; i.c.v.) or saline (10 ml; i.c.v.) injections. Nociceptive measurements were recorded 10 min after the second injection.
In the last set of experiments naloxone (10 mg; 0.0251 mmol; i.c.v.), CGP-35348 (20 mg; 0.0889 mmol; i.c.v.), or saline (10 ml; i.c.v.) was injected 15 min before i.c.v. administration of saline (10 ml) or CDP-choline (1 mmol). Nociceptive measurements were recorded 10 min after the second injection.
The dose and administration schedules of the abovementioned antagonists were selected from studies demonstrating the prevention of antinociceptive effects induced by the corresponding agonists (Malcangio et al., 1991; Drisdel and Gren; 2000; Mahmoudi and Zarrindast, 2002; Leite-Panissi et al., 2004; Hamurtekin and Gurun, 2006; Hamurtekin et al., 2007) .
Drugs
The following drugs were obtained from Sigma Chemical Co. (St. Louis, Missouri, USA): choline chloride, atropine sulfate, mecamylamine hydrochloride, HC-3, a-BgTx, CGP-35348. Carrageenan, CDP-choline and naloxone were purchased from Fluka Biochemicals Inc., (Buchs, Switzerland) and cytidine from Acros Organics (Geel, Belgium). All drugs were dissolved in physiological saline (0.9% sodium chloride) and were expressed as the free base of the drug.
Statistical analysis
Data are expressed as mean ± SEM in all cases. Groups of 5-10 rats were tested at each dose. Data were analyzed using one-way or two-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls test. A P value of less than 0.05 was considered significant.
Results
As shown in Fig. 1a , the injection of carrageenan into the right hindpaws of rats evoked a significant and longlasting reduction of the mechanical paw withdrawal threshold. In either hindpaw, the baseline paw withdrawal threshold was stable, and there was no significant difference between the bilateral hindpaws. The average baseline mechanical paw withdrawal threshold (n = 6) was 152.3 ± 2.1 g for the ipsilateral (right) hindpaw and 155.3 ± 2 g for the contralateral (left) hindpaw. Carrageenan injection (100 ml, 2%) into the right hindpaw produced marked inflammation (edema and erythema), as well as mechanical (Fig. 1a) hyperalgesia in the Contralateral hindpaw Ipsilateral hindpaw * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * Time course of mechanical hyperalgesia in inflammatory pain (a) and neuropathic pain (b) model of rats. Data are given as mean ± SEM of six animals for each group. ***P < 0.001 indicates a significant difference from the contralateral paw.
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injected paws, which peaked at 3 h after injection and showed little change in magnitude for the following 3 h. The contralateral, noninjected paw showed no detectable change compared with the baseline at all postcarrageenan time points (Fig. 1a) .
Neuropathic pain behaviors and mechanical paw withdrawal responses produced by chronic constriction injury
Rats that received CCI surgery to the left hindpaws showed limping and a mild degree of foot-drop on the affected paw, similar to that observed by Bennett and Xie, (1988) . Neither weight loss nor general weakness was observed. To confirm a decrease in the paw withdrawal threshold on the ipsilateral neuropathic hindpaws, as an indication of hyperalgesia, we compared the baseline withdrawal threshold between the ipsilateral and contralateral hindpaws. The average baseline mechanical paw withdrawal threshold of rats (n = 61) was 132.8±1.9 g for the ipsilateral hindpaw and 131.6 ± 1.8 g for the contralateral hindpaw. As shown in Fig. 1b , the CCI produced a significant and long-lasting reduction of the mechanical paw withdrawal threshold within seven days of sciatic nerve ligation, and the thresholds were reduced for the ipsilateral hindpaw from 132.8 ± 1.9 g to 77.6 ± 1 g 14 days after CCI.
Antihyperalgesic effect of intracerebroventricularly injected CDP-choline in inflammatory and neuropathic pain models
The antihyperalgesic effect of i.c.v. administered CDPcholine was investigated using mechanical paw withdrawal tests. In intraplantary carrageenan-administered rats, i.c.v. CDP-choline (0.5, 1, or 2 mmol), administered 3 h after carrageenan injection, increased the mechanical nociceptive paw withdrawal threshold (Fig. 2a) . CDP-cholineinduced antinociception reached its peak at 5 min after injection and returned to control levels over the following 20-30 min. ANOVA revealed that administration of CDPcholine caused significant effects on the nociceptive mechanical paw withdrawal threshold (Fig. 2a) In neuropathic rats that received CCI, CDP-choline (0.5, 1, or 2 mmol; i.c.v.), administered 14 days after CCI, increased the mechanical nociceptive paw withdrawal threshold in a dose-dependent and time-dependent manner (Fig. 2b) . CDP-choline-induced antinociception reached maximum values at 10 min after injection and returned to control levels within 20-50 min (Fig. 2b) . The increase in the withdrawal threshold after the highest dose of CDP-choline (2 mmol) was much greater and longer lasting than lower doses (Fig. 2b) . Two-way ANOVA revealed a significant effect of CDP-choline dose [F(3,23) = 51.1; P < 0.001], treatment time [F(8,183) = 48.5; P < 0.001], and a significant dosetime interaction [F(24,183) = 9.4; P < 0.001] on the nociceptive mechanical paw withdrawal threshold (Fig. 2b) . To test whether i.c.v.-injected equimolar doses of choline and cytidine, the immediate hydrolysis products of CDPcholine, could produce independent antihyperalgesic effects in acute inflammatory and neuropathic pain models, 1 mmol CDP-choline, choline, cytidine, or saline (10 ml) was injected 3 h after carrageenan injection or 14 day after the CCI procedure. In intraplantary carrageenan-administered rats, choline (1 mmol; i.c.v.) produced an antihyperalgesic response, as we have observed with an equimolar dose of CDP-choline (1 mmol; i.c.v.). Cytidine Paw withdrawal threshold (g) 300 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * Dose of CDP-choline (μmol) 0 0.5 1.0 2.0
Effect of intracerebroventricularly (i.c.v.)-injected cytidine-5 0 -diphosphate-choline (CDP-choline) (0.5, 1, and 2 mmol) or saline (10 ml) on mechanical paw withdrawal threshold in inflammatory (a) and neuropathic pain (b) models. Data are given as mean ± SEM of 6-9 animals for each group. *P < 0.05 and ***P < 0.001 significantly different from the values observed in the saline group.
(1 mmol; i.c.v.) partially, but significantly, induced an antihyperalgesic effect (Fig. 3a) . Two-way ANOVA indicated a significant effect of choline and CDP-choline treatment, time, and treatment-time interaction on the mechanical paw withdrawal threshold [F(3,25) = 34.8, P < 0.001; F(9,211) = 113.2, P < 0.001; and F(27,211) = 21.7, P < 0.001, respectively].
In neuropathic rats that received CCI, either choline (1 mmol; i.c.v.) or cytidine (1 mmol; i.c.v.) significantly induced an antihyperalgesic effect (Fig. 3b) . The paw withdrawal threshold obtained with choline injection was close to that obtained with an equimolar dose of CDPcholine (Fig. 3b) . ANOVA indicated a statistically significant effect of choline and CDP-choline treatment, time, and treatment-time interaction on the mechanical paw withdrawal threshold [F(3,22) = 43.4, P < 0.001; F(6,129) = 66.4, P < 0.001; and F(18,129) = 12.2, P < 0.001, respectively].
Effects of HC-3, mecamylamine, atropine, and a-BgTx pretreatment on the antihyperalgesic response to CDP-choline in inflammatory and neuropathic pain models
To investigate whether the CDP-choline produced antihyperalgesic effect was because of increased presynaptic cholinergic mechanisms, the rats were pretreated with HC-3 (1 mg; i.c.v.), a high-affinity neuronal choline uptake inhibitor. HC-3 pretreatment abolished the antihyperalgesic response to CDP-choline (1 mmol; i.c.v.) following the administration of mechanical paw pressure in intraplantary carrageenan-administered [F(1,11) = 8.4; P < 0.05] (Fig. 4a Paw withdrawal threshold (g) 300 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * Effects of intracerebroventricularly (i.c.v.)-injected equimolar doses of cytidine-5 0 -diphosphate-choline (CDP-choline) (1 mmol), choline (1 mmol), or cytidine (1 mmol) on mechanical paw withdrawal threshold in inflammatory (a) and neuropathic pain (b) models. Data are given as the mean ± SEM of 6-10 animals for each group. *P < 0.05, **P < 0.01 and ***P < 0.001 significantly different from the values observed in the saline group. Effects of hemicholinium-3 (HC-3) pretreatment on the increase in paw withdrawal threshold induced by cytidine-5 0 -diphosphate-choline (CDP-choline) in inflammatory pain (a) and neuropathic pain (b) models. Rats were pretreated with saline [(10 ml; intracerebroventricularly (i.c.v.)], or HC-3 (1 mg; i.c.v.), 15 min before i.c.v. administration of saline (10 ml) or CDP-choline (1 mmol). Nociceptive measurements of rats in the mechanical paw-pressure test were recorded 10 min after the second injection. Data are given as the mean ± SEM. of 6-9 animals for each group. ***P < 0.001 significantly different from the values observed in the saline group.
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and CCI-induced neuropathic rats [F(1,10) = 36.8; P < 0.001] (Fig. 4b) . HC-3 pretreatment alone had no significant effect on mechanical nociceptive threshold in rats ( Fig. 4a and b) .
To further evaluate the type of central cholinergic receptors that might be involved in the antihyperalgesic effects of CDP-choline, rats were pretreated with mecamylamine (50 mg; i.c.v.), a nonselective nicotinic cholinergic receptor antagonist; atropine (10 mg; i.c.v.), a nonselective muscarinic cholinergic receptor antagonist; a-BgTx (2 mg; i.c.v.), an a7nAChR antagonist; or saline (10 ml; i.c.v.). Mecamylamine and a-BgTx pretreatments blocked the antihyperalgesic responses after CDP-choline administration (1 mmol; i.c.v.) in both intraplantary carrageenan-administered rats [F(1,11) = 30.4, P < 0.001; F(1,11) = 30.2, P < 0.001, respectively] and in CCI-induced neuropathic rats [F(1,10) = 30.2, P < 0.001; F(1,10) = 18.6, P < 0.01, respectively], whereas atropine did not change the responses in either model [F(1,11) = 0.2, NS; F(1,11) = 0.1, NS, respectively] ( Fig. 5a and b) . Pretreatment with mecamylamine, atropine, or a-BgTx alone had no significant effect on the paw withdrawal threshold (Fig. 5a and b) .
Effects of naloxone and CGP-35348 pretreatment on antihyperalgesic response to CDP-choline in inflammatory and neuropathic pain models
To determine whether the CDP-choline-produced antihyperalgesic effects were because of supraspinal opioidergic and GABAergic receptors, the rats were pretreated with naloxone, a nonspecific opioid receptor antagonist (10 mg (Fig. 6a and b) . Antagonist pretreatment alone had no significant effect on the paw withdrawal threshold in either model ( Fig. 6a and b) .
Discussion
These data show that i.c.v. administration of CDP-choline produces a potent antihyperalgesic effect in carrageenaninduced inflammatory and CCI-induced chronic neuropathic pain models. These data also show that supraspinal a7nAChRs and GABA B receptors mediate antihyperalgesic responses to i.c.v. CDP-choline administration in both models, whereas opioid receptors mediate antihyperalgesic responses to i.c.v. CDP-choline administration only in the neuropathic pain model. CDP-choline is a naturally occurring endogenous nucleotide that is present in cells throughout the body and has been extensively used for the treatment of different neurodegenerative disorders, such as Alzheimer's Disease (Cacabelos et al., 1993; 2000; Amenta et al., 2001; Adibhatla and Hatcher, 2005) , memory deficiencies (Suryani et al., 1988; Amenta et al., 2001 ) and cerebral ischemic diseases (D'Orlando and Sandage, 1995; Wurtman, 1999; Warach et al., 2000; Adibhatla and Hatcher, 2005) . We have previously shown that i.c.v. administration of CDP-choline induced antinociceptive effects in acute pain models (Hamurtekin and Gurun, 2006) . In this study, in agreement with our previous study, CDP-choline induced dosedependent and time-dependent antihyperalgesic effects in inflammatory and neuropathic pain models (Fig. 2) . Effects of atropine, mecamylamine, and a-bungarotoxin (a-BgTx) pretreatments on the increase paw withdrawal threshold induced by cytidine-5 0 -diphosphate-choline (CDP-choline) in inflammatory pain (a) and neuropathic pain (b). Rats were pretreated with saline [(10 ml; intracerebroventricularly (i.c.v.)], atropine (10 mg; i.c.v.), mecamylamine (50 mg; i.c.v.), or a-BgTx (2 mg; i.c.v.), 15 min before i.c.v. administration of saline (10 ml) or CDP-choline (1 mmol). Nociceptive measurements of rats were recorded 10 min after the second injection. Data are given as the mean ± SEM of 6-9 animals for each group. **P < 0.01 and ***P < 0.001 significantly different from the values observed in the saline group.
i.c.v. administration of an equimolar dose of choline mimics the antihyperalgesic effect of CDP-choline in both models of chronic pain (Fig. 3) . HC-3 is a drug known to inhibit choline uptake by cholinergic neurons and to block the choline-induced increase in ACh concentrations (Koshimura et al., 1990) . The antihyperalgesic effects of CDPcholine could be due to the activation of presynaptic cholinergic mechanisms by elevated brain choline and ACh levels, as revealed by HC-3 inhibition (Fig. 4) .
To further investigate the receptor involved in the antihyperalgesic effects of CDP-choline, we used the nonselective cholinergic receptor antagonists atropine and mecamylamine. The antihyperalgesic effects of central CDP-choline were blocked by central pretreatment with the nicotinic receptor antagonist mecamylamine (Fig. 5 ), but not with the muscarinic receptor antagonist atropine (Fig. 5) . In earlier studies, atropine (10 mg, i.c.v.) abolished the increase in blood pressure (Savci et al., 2002) and the increases in serum GH and LH levels (Cavun and Savci, 2004) induced by the same dose of i.c.v. CDP-choline. Thus, the atropine dose used in this study is sufficient to block the central muscarinic effects of CDP-choline. Furthermore, the failure of atropine to alter antihyperalgesic responses to CDP-choline supports our previous results (Hamurtekin and Gurun, 2006) .
In this study, we also demonstrated the involvement of central a7-selective nicotinic ACh receptors in the antihyperalgesic effects of centrally administered CDPcholine in carrageenan-induced inflammatory pain. Neuronal nAChRs are part of a complex family of ligand-gated ion channels that comprise five subunit proteins and are known to play an important role in pain transmission. On the basis of sequence homology, neuronal nAChR subunits are subdivided into a and b types, nine a (a2-a10) and three b (b2-b4) subunits of which have been cloned. The most abundant CNS subtype combinations are the a4b2 heteromer and the a7 homomeric pentamer (Decker et al., 2004; Vincler, 2005) . It is well known that the neuronal a7nAChR is a homopentameric nAChR and belongs to the pharmacological class of nicotinic receptors that have a high binding affinity for a-BgTx (Drisdel and Gren, 2000) . In this study, in agreement with our previous results (Hamurtekin and Gurun, 2006) , pretreatment with a-BgTx significantly attenuated and/or blocked the antihyperalgesic response to CDP-choline in the inflammatory and neuropathic pain models in rats (Fig. 5) . Evidence for the analgesic efficacy of a7nAChRs was first demonstrated with the inhibition of nicotine-induced antinociception by the a7nAChR antagonists methyllycaconitine and a-BgTx in acute pain models in mice (Damaj et al., 1998 (Damaj et al., , 2000 . More recently, it has been shown in mice that the a7nAChR-selective agonist choline has antinociceptive and anti-inflammatory effects on either the late phase of the formalin test or on postoperative pain (Wang et al., 2005; Rowley et al., 2010) . Furthermore, Medhurst et al. (2008) demonstrated that a7nAChR agonists have antihyperalgesic properties in a rat model of inflammatory pain, which seems to be mediated through a central mechanism. However, it is well known that choline also acts as a potent, endogenous agonist at a4b4nAChR (Zwart and Vijverberg, 2000) . However, in this study, we have only used an antagonist for a7nAChR, a-BgTx, so the answer to this question will require further investigation.
Our results indicate that cholinergic activation plays a primary role in the antihyperalgesic effects of CDPcholine in the inflammatory and neuropathic pain models. However, cholinergic activation may not be the only system mediating the antihyperalgesic effect of Effects of naloxone and CGP-35348 pretreatments on the increase paw withdrawal threshold induced by cytidine-5 0 -diphosphate-choline (CDP-choline) in inflammatory pain (a) and neuropathic pain (b) models. Rats were pretreated with saline [(10 ml; intracerebroventricularly (i.c.v.) ], naloxone (10 ml; i.c.v.), or i.c.v.) 15 min before i.c.v. administration of saline (10 ml) or CDP-choline (1 mmol). Nociceptive measurements of rats in the mechanical paw-pressure test were recorded 10 min after the second injection. Data are given as the mean + SEM of 5-7 animals for each group. **P < 0.01 and ****P < 0.001 significantly dierent from the values observed in the control group.
The antihyperalgesic effect of CDP-choline Bagdas et al. 595 CDP-choline. As shown in Fig. 3 , centrally administered cytidine has a statistically significant antihyperalgesic effect. We previously showed that centrally administered cytidine produced an analgesic effect in acute pain models (Hamurtekin and Gurun, 2006) . Because of the fact that there are not many studies observing the supraspinal mechanisms responsible for the effects of cytidine in inflammatory and neuropathic pain states, we do not yet have sufficient information about the mechanisms. Peripheral adenosine receptors and central norepinephrine contributions have been mentioned as the possible mechanisms of the peripherally-injected cytidine in some studies (Carlezon et al., 2002; Yilmaz et al., 2008) . Because we have seen a significant antihyperalgesic effect with the administration of cytidine in this study, we are planning further studies to determine the possible mechanisms responsible for the antihyperalgesic effects of cytidine in different pain models. Nevertheless, considering that CDP-choline is a nucleotide, we may assume that purinergic receptors can contribute to the antihyperalgesic effects of cytidine. In accordance with our findings, some studies suggested the involvement of purinergic receptors in analgesia (Liu and Salter, 2005; Kennedy, 2005) and administration of some purinergic agonists produced analgesic effects in normal and neuropathic pain states (Fukui et al., 2001 (Fukui et al., , 2006 Okada et al., 2002) .
It has long been known that supraspinal opioid receptors are involved in the antinociceptive effects of nicotinic agonists (Zarrindast et al., 1996 (Zarrindast et al., , 1997 Bouaziz et al., 1996; Beilin et al., 1997) . Our present data suggest that the activation of supraspinal opioid receptors is involved in the antinociceptive effects of CDP-choline in the neuropathic pain model but did not contribute to the antihyperalgesic effect of centrally administered CDPcholine in the inflammatory pain model in rats (Fig. 6) . Pretreatment with i.c.v.-administered naloxone fully reversed the analgesic effect of morphine on carrageenan-induced acute inflammatory pain in rats (data not shown). In addition, the same dose of naloxone antagonized the antinociceptive effect produced by centrally administered CDP-choline in acute pain models (Hamurtekin and Gurun, 2006) . The interactions of the opioidergic system with the cholinergic system in the modulation of pain are quite complicated, although it is clear that the two systems interact in more than one way (Abe et al., 2002; Millan, 2002; Leite-Panissi et al., 2004) . Despite the well-known efficacy of opioids in inflammatory pain states, we do not have sufficient information about the role of opioid receptors in nicotinic-induced analgesia at the supraspinal level in inflammatory pain states. However, there are some studies that are in good accordance with our findings. In formalin tests, naloxone failed to block the antinociceptive effects of a novel nicotinic cholinergic drug, sazetidine-A, and choline (Wang et al., 2005; Cucchiaro et al., 2008) . In addition, supraspinal m-opioid receptors have been shown to play a role in neuropathic pain states Zhao et al., 2006 Zhao et al., , 2007 . Therefore, we assume that different mechanisms, other than the supraspinal opioidergic system, may contribute to the antihyperalgesic effects of CDP-choline in carrageenan-induced inflammatory pain. Consequently, the answer to this question requires further investigation.
GABA is the main central inhibitory neurotransmitter, and GABAergic neurons are widely distributed throughout the central nervous system (Enna and McCarson, 2006) . It is also well established that the GABAergic system is a target for a variety of central pharmacological agents, including analgesics (Sawynok and LaBella, 1982; Iversen, 2004) . GABAergic and cholinergic neurons may have a similar distribution in the CNS, and the activation of certain supraspinal nAChRs enhances the release of GABA from nerve terminals. Furthermore, the same studies demonstrated that a7nAChRs regulate GABAergic transmission in a neuron-type-specific way in some brain regions (Alkondon et al., 1999 (Alkondon et al., , 2000 Alkondon and Albuquerque, 2001 ). Our results are in agreement with other published studies, as well as with our own previous findings (Hamurtekin et al., 2007) and suggest a possible interaction between the GABAergic and cholinergic systems by implicating supraspinal GABA B receptors in the mediation of the CDP-cholineinduced antinociceptive effect. In fact, i.c.v. administration to rats of a GABA B receptor antagonist, CGP-35348, effectively attenuated the antihyperalgesic response to CDP-choline in the inflammatory and neuropathic pain models. However, such treatment had no effect on the baseline pain threshold (Fig. 6 ).
Taken together, the results from this study demonstrate, for the first time, that i.c.v.-administered CDP-choline is able to produce a dose-dependent antihyperalgesic effect in carrageenan-induced inflammatory and CCI-induced neuropathic pain models in rats by potentiating endogenous cholinergic activity. The activation of supraspinal nicotinic receptors, predominantly a7nAChRs, through the activation of presynaptic cholinergic mechanisms, mediates the antihyperalgesic responses to i.c.v. injection of CDP-choline. The present results also show that, while supraspinal GABA B receptors are involved in the antihyperalgesic effect of CDP-choline in both models, central opioid receptors have a role only in the neuropathic pain model. Although further studies will be required, these results may provide additional evidence for the utility of centrally active agonists of a7nAChRs in the management of inflammatory and neuropathic pain.
